Dr. Alfred P. Spada

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/w - [Cached Version]
  Published on: 11/1/2006    Last Visited: 5/19/2007  

  suffering from liver disease," said Alfred P. Spada, Ph.D., Senior Vice President of Research and Development at Conatus.

• 
  www.biospace.com/news_story.aspx?NewsEntityId=76328 - [Cached Version]
  Published on: 11/5/2007    Last Visited: 11/6/2007  

  Our initial goal for the development of CTS-1027 is to establish safety and efficacy in patients infected with HCV who have failed or can not tolerate standard of care," stated Alfred Spada, Ph.D., SVP Research and Development.
  ...
  smento@conatuspharma.com, or Alfred P. Spada, Ph.D., Sr. VP R & D,+1-858-457-7223, aspada@conatuspharma.com, both of Conatus Pharmaceuticals

• 
  www.idun.com/text/news/00news/010501.htm - [Cached Version]
  Published on: 1/5/2001    Last Visited: 7/31/2001  

  The new facility has expanded lab space for our enzymology , high throughput screening , and chemistry groups as well as increased cell culture and vivarium capabilities with room for future growth , commented Al Spada , Ph.D. , Vice President , Pharmaceutical Development at Idun.Our capacity to produce compounds will be increased to kilogram scale , which is a significant step for a small company.In addition , we are expanding our medicinal chemistry department to accelerate our ongoing discovery programs..
  
  Idun Pharmaceuticals , Inc. is a biopharmaceutical company based in San Diego , CA.It creates innovative human therapeutics with a primary focus on controlling apoptosis , or programmed cell death.Idun believes that controlling the cell death process will have utility in treating cancer , neurodegenerative diseases , ischemic disorders and cardiovascular disease.

• 
  www.lead411.com/executives.taf?_function=alpharequest&l - [Cached Version]
  Published on: 5/13/2008    Last Visited: 5/13/2008  

  Alfred Spada

• 
  www.lead411.com/company.taf?_function=detail&Company_ui - [Cached Version]
  Published on: 3/27/2008    Last Visited: 4/1/2008  

  Alfred Spada [VCard] SVP Research/Development/Co-Founder

• 
  www.conatuspharma.com/news/pr_110507.htm - [Cached Version]
  Published on: 11/5/2007    Last Visited: 12/1/2007  

  Our initial goal for the development of CTS-1027 is to establish safety and efficacy in patients infected with HCV who have failed or can not tolerate standard of care", stated Alfred Spada, Ph.D., SVP Research and Development.

• 
  BioExchange - Life Sciences and Biotechnology Resource... - [Cached Version]
  Published on: 1/5/2001    Last Visited: 6/16/2001  

  The new facility has expanded lab space for our enzymology , high throughput screening , and chemistry groups as well as increased cell culture and vivarium capabilities with room for future growth , commented Al Spada , Ph.D. , Vice President , Pharmaceutical Development at Idun.Our capacity to produce compounds will be increased to kilogram scale , which is a significant step for a small company.In addition , we are expanding our medicinal chemistry department to accelerate our on-going discovery programs..
  
  Idun Pharmaceuticals , Inc. is a biopharmaceutical company based in San Diego , CA.It creates innovative human therapeutics with a primary focus on controlling apoptosis , or programmed cell death.Idun believes that controlling the cell death process will have utility in treating cancer , neurodegenerative diseases , ischemic disorders and cardiovascular disease.

• 
  Conatus Pharmaceuticals » About Us » Management - [Cached Version]
  Published on: 12/1/2007    Last Visited: 12/1/2007  

  Alfred P. Spada, Ph.D., SVP Research and Development and Co-founder
  
  Dr. Spada has over twenty years of experience in the pharmaceutical and biotechnology industries.He has co-authored more than 50 scientific publications and is inventor on more than 70 patents.From 2000 to 2005, Dr. Spada was Vice President of Pharmaceutical and Preclinical Development at Idun Pharmaceuticals where he was responsible for managing internal research and development activities, and Idun's external partnerships.
  
  Prior to joining Idun, Dr. Spada was a Department Director at Aventis Pharmaceuticals (formerly Rhone-Poulenc Rorer) where he was responsible for medicinal and analytical chemistry.From 1990 to 2000, his teams worked on a wide variety of enzyme-based and GCPR targets, resulting in the identification of clinical candidates for treatment of acute myocardial infarction, thrombotic disorders, coronary restenosis, lipid lowering, diabetes and cancer.
  
  From 1985 to 1990, Dr. Spada held a series of positions of increasing responsibility at Rorer Pharmaceuticals, Inc.His team focused on developing compounds for use in the treatment of congestive heart failure and myocardial ischemia.
  
  Dr. Spada was awarded a B.S. degree in Chemistry with High Distinction from Worcester Polytechnic Institute and a Ph.D. in Chemistry from the Massachusetts Institute of Technology.He also conducted post-doctoral research at Yale University.

• 
  Conatus Pharmaceuticals » Contact Us - [Cached Version]
  Published on: 12/1/2007    Last Visited: 12/1/2007  

  Alfred P. Spada, Ph.D.Senior Vice President, Research and Development, and Co-Founderaspada@conatuspharma.com

• 
  Connect Newsletter, The Bits - [Cached Version]
  Published on: 11/21/1999    Last Visited: 1/30/2001  

  Idun Pharmaceuticals, Inc. has announced the appointment of Al Spada, Ph.D., to the recently created position of Vice President of Pharmaceutical Development.Dr. Spada, whose duties will include overseeing medicinal and process chemistry as well as pharmacology and formulation development for Idun's clinical drug candidates, joins Idun from Aventis Pharmaceuticals where he was the Department Director of Medicinal Chemistry.
  
  c. ResMed Back on Business Week's List of Top Growth Companies
  
  Congratulations to ResMed Inc., named to Business Week's top 100 growth companies list for the second year in a row.Ranked this year at # 58 (up from last year's ranking of 67), ResMed was only one of 31 companies to repeat, and only one of two local companies on the list.Carlsbad-based Invitrogen came in at # 88 on the list.

Page:  1 2